Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,743.67
(
0.66%
)
US TECH 100
24,132.80
(
0.49%
)
Dow Jones
47,367.81
(
0.90%
)
Brent Oil
99.56
(
1.28%
)
Bitcoin
73,975.62
(
-1.16%
)
News Focus
News Focus
Post# of 257251
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (16) Keep Next 10 Report Keyboard Shortcuts
Replies (16) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122790
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 61429

Friday, 05/27/2011 3:22:13 PM

Friday, May 27, 2011 3:22:13 PM

Post# of 257251

“Once is happenstance, twice is coincidence, three times is enemy action, Mr. Bond.” *


1. Zetia showed no clinical benefit when added to Zocor in the ENHANCE study, despite raising HDL the way it was supposed to (#msg-25991228).

2. TriCor failed to show a statsig benefit when added to Zocor in the ACCORD study, despite lowering triglycerides and raising HDL the way it was supposed to (#msg-47808450).

3. Niaspan showed no clinical benefit when added to Zocor in the AIM-HIGH study, despite raising HDL the way it was supposed to (#msg-63617748).


We have enemy action.

*From Goldfinger.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (16) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (16) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now